Clinical Trial: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07856004) titled 'A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment' on Sept. 29.

Brief Summary: The goal of this study is to understand how the body processes tacabrutideg in adults with different levels of liver function (normal, moderate impairment, and severe impairment).

Study Start Date: Oct. 22

Study Type: INTERVENTIONAL

Condition: Hepatic Impairment Healthy Adult Participants

Intervention: DRUG: Tacabrutideg

Single dose of tacabrutideg administered orally.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: BeOne Medicines

Disclaimer: ...